Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -37.11 Million SEK | 2.07% |
| 2022 | -37.79 Million SEK | 27.25% |
| 2021 | -52.1 Million SEK | -147.44% |
| 2020 | -21.05 Million SEK | -126.03% |
| 2019 | -9.31 Million SEK | -21173299900.06% |
| 2018 | -0.04 SEK | -4300.0% |
| 2017 | - SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.26 Million SEK | 0.4% |
| 2024 Q3 | -1.61 Million SEK | 91.35% |
| 2024 Q2 | -18.66 Million SEK | -101.47% |
| 2023 Q2 | -13.9 Million SEK | -94.72% |
| 2023 FY | - SEK | 14.03% |
| 2023 Q4 | -7.15 Million SEK | -22.11% |
| 2023 Q3 | -5.86 Million SEK | 57.85% |
| 2023 Q1 | -7.14 Million SEK | 44.63% |
| 2022 Q3 | -9.87 Million SEK | -6.0% |
| 2022 Q1 | -5.81 Million SEK | 80.0% |
| 2022 FY | - SEK | 27.25% |
| 2022 Q2 | -9.32 Million SEK | -60.28% |
| 2022 Q4 | -12.89 Million SEK | -30.54% |
| 2021 FY | - SEK | -147.44% |
| 2021 Q4 | -29.07 Million SEK | -418.48% |
| 2021 Q3 | -5.6 Million SEK | 50.53% |
| 2021 Q2 | -11.33 Million SEK | -85.99% |
| 2021 Q1 | -6.09 Million SEK | 37.34% |
| 2020 FY | - SEK | -126.03% |
| 2020 Q4 | -9.72 Million SEK | -1046.92% |
| 2020 Q3 | 1.02 Million SEK | 0.0% |
| 2019 FY | - SEK | -21173299900.06% |
| 2018 FY | - SEK | -4300.0% |
| 2017 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 84.378% |
| Ziccum AB (publ) | -20.34 Million SEK | -82.475% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1856050.0% |
| BioArctic AB (publ) | 275.38 Million SEK | 113.479% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1684.567% |
| Mendus AB (publ) | -97.84 Million SEK | 62.064% |
| Genovis AB (publ.) | 64.57 Million SEK | 157.485% |
| Intervacc AB (publ) | -68.98 Million SEK | 46.189% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -176.368% |
| Active Biotech AB (publ) | -43.88 Million SEK | 15.421% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 218.198% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 32.272% |
| Aptahem AB (publ) | -10 Million SEK | -270.848% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 88.308% |
| Kancera AB (publ) | -61.88 Million SEK | 40.023% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 421.404% |
| Fluicell AB (publ) | -25.91 Million SEK | -43.239% |
| Saniona AB (publ) | -69.69 Million SEK | 46.741% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -206.667% |
| Biovica International AB (publ) | -119.5 Million SEK | 68.94% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 12.09% |
| AcouSort AB (publ) | -16.7 Million SEK | -122.23% |
| Xintela AB (publ) | -53.47 Million SEK | 30.581% |
| Abliva AB (publ) | -93.6 Million SEK | 60.346% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 88.368% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -38.592% |
| OncoZenge AB (publ) | 7.26 Million SEK | 610.859% |
| Amniotics AB (publ) | -27.14 Million SEK | -36.753% |
| 2cureX AB (publ) | -35.13 Million SEK | -5.644% |
| CombiGene AB (publ) | -35.33 Million SEK | -5.046% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -161.089% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 89.908% |
| Camurus AB (publ) | 562.54 Million SEK | 106.598% |
| Corline Biomedical AB | -1.69 Million SEK | -2095.092% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 78.584% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -0.257% |
| I-Tech AB | 30.34 Million SEK | 222.323% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 94.805% |
| Cyxone AB (publ) | -20.41 Million SEK | -81.831% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 63.77% |
| Biosergen AB | 228 Thousand SEK | 16380.263% |
| Cantargia AB (publ) | -284.31 Million SEK | 86.944% |
| NextCell Pharma AB | -40.98 Million SEK | 9.433% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 78.142% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -117.267% |
| Nanologica AB (publ) | -62.11 Million SEK | 40.245% |
| SynAct Pharma AB | -222.7 Million SEK | 83.332% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 15.371% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 12096.587% |
| LIDDS AB (publ) | -39.67 Million SEK | 6.431% |
| BioInvent International AB (publ) | -312.7 Million SEK | 88.13% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 88480.676% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 83.974% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -321.21% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 67.696% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -89.586% |
| Simris Alg AB (publ) | -22.36 Million SEK | -65.984% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 73.647% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 86.839% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 65.807% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -223.646% |